SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
SCHEDULE 13G/A
 
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
 

Syndax Pharmaceuticals, Inc.

(Name of Issuer)
 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)
 

87164F105

(CUSIP Number)
 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
¨ Rule 13d-1(b)
ý Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 10 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 87164F10513G/APage 2 of 10 Pages

 

1

NAME OF REPORTING PERSON

 

Point72 Asset Management, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,834,499

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,834,499

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,834,499

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.3%

12

TYPE OF REPORTING PERSON

PN

         

 

 

CUSIP No. 87164F10513G/APage 3 of 10 Pages

 

 

1

NAME OF REPORTING PERSON

 

Point72 Capital Advisors, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,834,499

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,834,499

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,834,499

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.3%

12

TYPE OF REPORTING PERSON

CO

         

 

 

CUSIP No. 87164F10513G/APage 4 of 10 Pages

 

 

1

NAME OF REPORTING PERSON

 

Cubist Systematic Strategies, LLC

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

      0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

12

TYPE OF REPORTING PERSON

OO

         

 

 

CUSIP No. 87164F10513G/APage 5 of 10 Pages

 

 

1

NAME OF REPORTING PERSON

 

Point72 Middle East FZE

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United Arab Emirates

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

12

TYPE OF REPORTING PERSON

      OO

         

 

CUSIP No. 87164F10513G/APage 6 of 10 Pages

 

 

1

NAME OF REPORTING PERSON

 

Point72 Asia (Singapore) Pte. Ltd.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

Singapore

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

0

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0%

12

TYPE OF REPORTING PERSON

      OO

         

 

CUSIP No. 87164F10513G/APage 7 of 10 Pages

 

 

1

NAME OF REPORTING PERSON

 

Steven A. Cohen

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)¨

(b)x

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

2,834,499

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

2,834,499

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,834,499

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.3%

12

TYPE OF REPORTING PERSON

IN

         

 

 

CUSIP No. 87164F10513G/APage 8 of 10 Pages

  

Item 1(a). Name of Issuer.
    Syndax Pharmaceuticals, Inc. (the “Issuer”).
Item 1(b). Address of Issuer’s Principal Executive Offices.
  35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts 02451.

 

Item 2(a). Name of Person Filing.
 

This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.0001 per share (“Shares”), of the Issuer held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by an investment fund managed by Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to Shares that were held by an investment fund it manages; (iv) Point72 Middle East FZE (“Point72 Middle East”) with respect to Shares that were held by an investment fund it manages; (v) Point72 Asia (Singapore) Pte. Ltd. (“Point72 Asia (Singapore)”) with respect to Shares that were held by an investment fund it manages; and (vi) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc., and Shares that were beneficially owned by Cubist Systematic Strategies, Point72 Middle East, and Point72 Asia (Singapore).

 

Item 2(b). Address of Principal Business Office.
  The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001; (iii) Point72 Middle East is One Central, Dubai World Trade Centre, The Offices 3 Sheikh Zayed Road, Dubai, United Arab Emirates; and (iv) Point72 Asia (Singapore) is 50 Collyer Quay, OUE Bayfront, #08-03, Singapore, 049321.

 

Item 2(c). Place of Organization.
  Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.  Point72 Middle East is a limited liability free zone establishment.  Point72 Asia (Singapore) is a Singapore private company limited by shares. Mr. Cohen is a United States citizen.

 

Item 2(d). Title of Class of Securities.
  Common Stock, par value $0.0001 per share.
   
Item 2(e). CUSIP Number.
  87164F105

 

Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
  Not applicable.

 

 

CUSIP No. 87164F10513G/APage 9 of 10 Pages

 

 

Item 4. Ownership.

 

 

The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. Such information is as of the close of business on December 31, 2023.

 

Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72 Middle East, Point72 Asia (Singapore), and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages. Pursuant to an investment management agreement, Point72 Middle East maintains investment and voting power with respect to the securities held by an investment fund it manages. Pursuant to an investment management agreement, Point72 Asia (Singapore) maintains investment and voting power with respect to the securities held by an investment fund it manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, Point72 Middle East, and Point72 Asia (Singapore). The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

 

  The aggregate percentage of the Shares reported to be beneficially owned by each Reporting Person is based on 84,809,736 Shares outstanding as of December 19, 2023, as reported in Exhibit 99.1 attached to the Issuer’s 8-K filed with the Securities and Exchange Commission on December 20, 2023.
   
Item 5. Ownership of Five Percent or Less of a Class.
  If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [X].
   
Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
  See Item 2(a).
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
  Not applicable.
   
Item 8. Identification and Classification of Members of the Group.
  Not applicable.
   
Item 9. Notice of Dissolution of Group.
  Not applicable.

 

Item 10. Certification.
  By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

CUSIP No. 87164F10513G/APage 10 of 10 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

Date: February 14, 2024  
  POINT72 ASSET MANAGEMENT, L.P.
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person
   
  POINT72 CAPITAL ADVISORS, INC.
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person
   
  CUBIST SYSTEMATIC STRATEGIES, LLC
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person
   
  POINT72 MIDDLE EAST FZE
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person
   
  POIN72 ASIA (SINGAPORE) PTE. LTD.
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person
   
  STEVEN A. COHEN
   
  By:  /s/ Jason M. Colombo
  Name:  Jason M. Colombo
  Title:    Authorized Person

 

 


Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Syndax Pharmaceuticals Charts.
Syndax Pharmaceuticals (NASDAQ:SNDX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Syndax Pharmaceuticals Charts.